Evidence map›Paper›PMID 30218008›Full record

ArticleLeukemia2018

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

P G Richardson, C C Hofmeister, N S Raje, D S Siegel, S Lonial, J Laubach, Y A Efebera, D H Vesole, A K Nooka, J Rosenblatt and 8 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

P G RichardsonJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. paul_richardson@dfci.harvard.edu.
C C HofmeisterDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
N S RajeMassachusetts General Hospital, Boston, MA, USA.
D S SiegelJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
S LonialDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
J LaubachJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Y A EfeberaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
D H VesoleJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
A K NookaDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
J RosenblattBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
D DossJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
M H ZakiCelgene Corporation, Summit, NJ, USA.
A BensmaineCelgene Corporation, Summit, NJ, USA.
J HerringCelgene Corporation, Summit, NJ, USA.
Y LiCelgene Corporation, Summit, NJ, USA.
L WatkinsCelgene Corporation, Summit, NJ, USA.
M S ChenCelgene Corporation, Summit, NJ, USA.
K C AndersonJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the publication of this article, the authors noted that the pomalidomide dose for the additional SC cohort in Fig. 1 was incorrectly listed. The correct dose for pomalidomide in the additional SC cohort should be the maximum tolerated dose of 4 mg/day, not 2 mg/day as listed in the original Fig. 1. The authors apologize for any inconvenience caused.

Identifiers

PMID30218008
PMCPMC6887838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.